Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Accumulated Expenses for 6 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 348.94% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Dec 2025, up 348.94%, and an annual FY2025 reading of $4.9 million, up 348.94% over the prior year.
  • Other Accumulated Expenses was $4.9 million for Q4 2025 at Xeris Biopharma Holdings, down from $51.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $51.3 million in Q3 2025 and bottomed at $337000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $14.3 million, with a median of $11.8 million recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses crashed 95.03% in 2022, then skyrocketed 6295.85% in 2023.
  • Year by year, Other Accumulated Expenses stood at $2.0 million in 2021, then soared by 746.4% to $16.8 million in 2022, then plummeted by 93.06% to $1.2 million in 2023, then dropped by 6.68% to $1.1 million in 2024, then soared by 348.94% to $4.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for XERS at $4.9 million in Q4 2025, $51.3 million in Q3 2025, and $33.2 million in Q2 2025.